San Francisco-based Alta Partners took the lead role in a €15 million round of venture financing for Kiadis Pharma, an oncology drug developer. The Amsterdam-based company is developing therapies for bone marrow transplants and the treatment of aggressive cancers. Its four most advanced products are currently in clinical trials, ranging from Phase I to entering Phase III. Kiadis Pharma's lead product is ATIR, which enables the use of mis-matched bone-marrow donors in transplantations for terminally ill blood cancer patients.
- check out the release on the round